Improve Bio - ground breaking science to defeat Pancreatic cancer

Improve Bio is developing proprietary biologics to target novel mechanism of resistance designed by leading Pancreatic cancer scientists.

About Improve Bio

Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla sit amet egestas eros. Sed feugiat id mauris eu cursus. Vestibulum sed urna ac ex ornare faucibus ac a magna. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

About Improve Bio
About Improve Bio

Leadership Team & PEN

Darshan Gandhi, M.D., M.B.A., Harvard AMP
CEO and Co-Founder
David Setboun, Pharm.D, M.B.A., Harvard AMP
Co-Founder
Eric Dutang, CPA,
MBA
COO/CFO
Simon Mazza-Lunn, Ph.D
Scientific Advisor
Professor Haiyong Han,
Ph.D
David Ting, MD
Professor Rolf Brekken,
Ph.D
Ravi Mistry,
MS, MBA
Business Advisor

Pancreatic Cancer Unmet Need

Increasing Incidence
  • 2nd largest killer by 2030
  • >95% Mortality
  • Surpassed breast cancer
Lack of Rx
  • Only 5 FDA approved Rx
  • Response rates <20-30%
  • No maintenance Rx
  • Relapse <6 months
  • 5-year survival 11%
Increasing Incidence
  • 2nd largest killer by 2030
  • >95% Mortality
  • Lower Threshold for approvals

Pancreatic Cancer Treatments have Significant Limitations

Targeted Therapy
  • Poor Penetration
  • Off-Target effects
  • Limited population
  • Small molecules
  • Sotorasib, Entrectinib, Rucaparib
Chemotherapy
  • Poor Penetration
  • Single agent response
  • rates<20%
  • Combination too toxic
  • Gemcitabine, 5-FU, Oxaliplatin, Irinotecan
Immunotherapy
  • Limited population MSI/TMB high
  • Suppressed TME
  • T-cell exhaustion
  • Poor penetration
  • Pembrolizumab Dostarlimab

Pancreatic Cancer Treatments have Significant Limitations

Mechanisms of Resistance and Our Solutions

Barriers
  • Mechanical resistance (IMP 001)
  • Cancer Evolution (IMP 002)
Solutions
  • Addressing thick surrounding stroma that prevents drugs from entering the cancer cells
  • Addressing epithelial-mesenchymal-transition
Technologies
  • ATP1A1 Ab targeting PDAC/fibroblasts TGF-beta/IL-1 bispecific/fusion protein (animal experiments)
  • ATP1A1 Ab targeting PDAC/fibroblasts (discovery phase)

Our Technologies

SABBR Platform
Bispecific complex protein IMP-001

Addressing Fibrotic Stroma
Cancer cell malignant signaling Fibroblast 

pro-fibrogenic signaling

Monoclonal antibody IMP-002

Epithelial-mesenchymal transition
Cancer cell/fibroblast interaction-mediated EMT signaling

Developing Assets to Improve ENTIRE Patient Journey

Current Patient Journey
STATUS QUO for DECADES

Ideal Patient Journey with
ImproveBio Interventions 

Join Our Mission

Reshape Care for one of the Most Aggressive cancers Worldwide
Contact Us